(Q37980084)

26 August 2017

2 references

21 October 2022

25 October 2022

Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV. (English)

1 reference

human immunodeficiency virus infectious disease

26 August 2017

0 references

HIV protease inhibitors

1 reference

1 reference

3

Irene T Weber

1 reference

26 August 2017

Arun K Ghosh

1

1 reference

26 August 2017

David D Anderson

series ordinal

2

1 reference

26 August 2017

Hiroaki Mitsuya

series ordinal

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

31 January 2012

1 reference

Angewandte Chemie International Edition

26 August 2017

20 February 2012

2 references

21 October 2022

25 October 2022

2 references

21 October 2022

25 October 2022

51

1 reference

26 August 2017

8

1 reference

26 August 2017

1778-1802

1 reference

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

26 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Molecular basis of human immunodeficiency virus drug resistance: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

HIV drug development: the next 25 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Strategies for antiviral therapy in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Active human immunodeficiency virus protease is required for viral infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Mutation rates among RNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Recombination in AIDS viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Raltegravir with optimized background therapy for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Novel targets for antiretroviral therapy: clinical progress to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Alternative splicing: regulation of HIV-1 multiplication as a target for therapeutic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Molecular Basis for Drug Resistance in HIV-1 Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Construction of a human immunodeficiency virus type 1 (HIV-1) library containing random combinations of amino acid substitutions in the HIV-1 protease due to resistance by protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

HIV-1 Protease: Structural Perspectives on Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Inhibitors of HIV-1 protease: a major success of structure-assisted drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Evolution of protein function, from a structural perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

The depth of chemical time and the power of enzymes as catalysts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

A perspective on enzyme catalysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

How enzymes work: analysis by modern rate theory and computer simulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Comparison of inhibitor binding in HIV-1 protease and in non-viral aspartic proteases: the role of the flap

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Structural and biochemical studies of retroviral proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

"Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Rational design of peptide-based HIV proteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Terpene trilactones from Gingko biloba: from ancient times to the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Biochemical studies on the fate of monensin in animals and in the environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Inhibitors of HIV-1 protease containing the novel and potent (R)-(hydroxyethyl)sulfonamide isostere

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Profile of darunavir in the management of treatment-experienced HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Molecular Characterization of Clinical Isolates of Human Immunodeficiency Virus Resistant to the Protease Inhibitor Darunavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Potent New Antiviral Compound Shows Similar Inhibition and Structural Interactions with Drug Resistant Mutants and Wild Type HIV-1 Protease †

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Design of substituted bis-Tetrahydrofuran (bis-THF)-derived Potent HIV-1 Protease Inhibitors, Protein-ligand X-ray Structure, and Convenient Syntheses of bis-THF and Substituted bis-THF Ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein–ligand X-ray studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Design of HIV-1 Protease Inhibitors with C3-Substituted Hexahydrocyclopentafuranyl Urethanes as P2-Ligands: Synthesis, Biological Evaluation, and Protein–Ligand X-ray Crystal Structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Design of HIV-1 Protease Inhibitors with Pyrrolidinones and Oxazolidinones as Novel P1′-Ligands To Enhance Backbone-Binding Interactions with Protease: Synthesis, Biological Evaluation, and Protein−Ligand X-ray Studies ∞

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Flexible Cyclic Ethers/Polyethers as Novel P2-Ligands for HIV-1 Protease Inhibitors: Design, Synthesis, Biological Evaluation, and Protein−Ligand X-ray Studies †

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Probing Multidrug-Resistance and Protein-Ligand Interactions with Oxatricyclic Designed Ligands in HIV-1 Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201102762

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

21 January 2018

1 reference

12 December 2020

Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases

1 reference

12 December 2020

Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients

1 reference

12 December 2020

Structural and functional constraints in the evolution of protein families

1 reference

12 December 2020

Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance

1 reference

12 December 2020

Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

1 reference

12 December 2020

New developments in HIV drug resistance

1 reference

12 December 2020

Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

1 reference

12 December 2020

The evolution of protein structures

1 reference

12 December 2020

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 reference

12 December 2020

Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation

1 reference

12 December 2020

Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring

1 reference

12 December 2020

Identifiers

DOI

10.1002/ANIE.201102762

1 reference

26 August 2017

0 references

1 reference